N-acetylcysteine for Idiopathic Pulmonary Fibrosis: A Systematic Review
10.6039/j.issn.1001-0408.2017.27.21
- VernacularTitle:N-乙酰半胱氨酸治疗特发性肺纤维化疗效的系统评价
- Author:
Dan LIU
1
;
Lingli ZHANG
;
Xuehua JIANG
;
Shuyan QUAN
;
Zhiqiang HU
;
Lucan JIANG
;
Ge GUI
Author Information
1. 四川大学华西药学院
- Keywords:
N-acetylcysteine;
Idiopathic pulmonary fibrosis;
Meta-analysis;
Therapeutic efficacy
- From:
China Pharmacy
2017;28(27):3820-3823
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To review therapeutic efficacy of N-acetylcysteine (NAC) for idiopathic pulmonary fibrosis (IPF),and to provide evidence-based reference.METHODS:Retrieved from Central database,PubMed,EMBase,CBM,CJFD,Wanfang database and VIP,randomized controlled trials or semi-randomized controlled trials about NAC (unlimited single drug or combination) vs.placebo/blank control in the treatment of IPF were collected.Meta-analysis was performed by using Rev Man 5.3 statistical software after data extraction and quality evaluation with Cochrane collaboration's bias risk assessment tool(2014 edition).RESULTS:A total of 10 studies were included(2 RCT,8 qRCT),involving 742 patients.Results of Meta-analysis showed that compared to placebo/blank control,NAC couldn't reduce the mortality of IPF patients [OR=1.14,95％ CI(0.50,2.62),P=0.76],but could significantly improve subjective symptom remission rate[OR=3.17,95％ CI (1.98,5.07),P＜0.001] and dyspnea score [SMD =-2.54,95 ％ CI (-5.02,-0.06),P=0.04].CONCLUSIONS:For IPF,NAC can't decrease the mortality of patients,but can relieve main symptoms and dyspnea.
